| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | dabogratinib FGFR3-altered low-grade intermediate risk non-muscle invasive bladder cancer (IR NMIBC) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 2 data readout example | dabogratinib FGFR3-altered low-grade intermediate risk non-muscle invasive bladder cancer (IR NMIBC) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 2 data readout example | dabogratinib FGFR3-altered low-grade intermediate risk non-muscle invasive bladder cancer (IR NMIBC) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Tyra Biosciences, Inc.$32.75
-0.26 (-0.79%)
C 51Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.93 B
EPS
-2.17
P/E Ratio
-
Value Trade
22.24 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
33.47 M
Operating CF
-32.57 M
Total Assets
412.04 M
Total Liabilities
24.46 M
Equity
387.57 M
D/E Ratio
12,345
-9.33 %
Week
-13.27 %
1 Month
4.41 %
3 Month
56.56 %
6 Month
8.6 %
5 Year
8.6 %
All Time
Cash Data
Cash Position
383.47 M
Monthly Burn
10.86 M
Runway
33.6 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
998.74 K
52 Week Range
8.75 - 40.65
% held by Insiders
25.7 %
% held by Institutions
88.04 %
Enterprise Value
1.55 B
Total Shares
53.91 M
Short %
22.33 %
Float Shares
28.09 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tyra Biosciences, Inc.
115Total events
4Upcoming
13Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 4
Event history 111
Q3 2026
◆Topline ReadoutDabogratinibClinical Data
Interim results from safety sentinel cohort of BEACH301
achondroplasia (ACH)source ↗
Jun 2026
◆Topline ReadoutDabogratinibClinical Data
Initial three-month complete response data from SURF302
intermediate risk non-muscle invasive bladder cancer (IR NMIBC)source ↗
May 26, 2026
◆Oral PresentationPresentation
TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 21, 2026
▲First Patient DosedDabogratinibTrial
Dosing patients with dabogratinib in Phase 2 SURF303 study for low-grade UTUC
low-grade UTUCsource ↗
May 2026
●Poster PresentationDabogratinibPresentation
Preclinical results presented at Fusion Conference on FGFR Biology
ACHsource ↗
Q2 2026
◆Topline ReadoutDabogratinibClinical Data
Interim results from safety sentinel cohort of BEACH301 expected
achondroplasiasource ↗
Drug Pipeline Intelligence
C51
Pipeline Score $1.3B
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored2.3x
rNPV / MCap Top 77%
Micro Cap (rank 211 of 911)
Percentile RankTyra Biosciences, Inc. carries a moderate pipeline score (51/100), with $3.4B risk-adjusted pipeline value, led by TYRA-300 in Low-grade NMIBC (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TYRA-300 Small molecule | Low-grade NMIBC | Phase 2 | NCT06995677 | 14% | $3.0B | RECRUITING | 90 | AVERAGE | C (44) | Sep 1, 2028 | MODERATE_RISK | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TYRA-300 | metastatic urothelial cancer | Phase 2 | 2025-03-27 | 6 out of 11 (54.5%) patients with FGFR3+ mUC | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 st Read More | |
TYRA-300 | metastatic urothelial cancer | Phase 2 | 2025-03-27 | 6 out of 11 (54.5%) patients with FGFR3+ mUC | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 st Read More | |
TYRA-300 | metastatic urothelial cancer | Phase 2 | 2025-03-27 | 6 out of 11 (54.5%) patients with FGFR3+ mUC | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 st Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TYRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TYRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TYRATYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences has partnered with the Bladder Cancer Advocacy Network to establish Upper Tract Urothelial Cancer (UTUC) Awareness Day on May 21. This initiative aims to raise awareness of UTUC, a rare cancer with limited treatment options. The collaboration seeks to enhance patient support and highlight the need for innovative research in this area. Tyra is also advancing its investigational drug, dabogratinib, in clinical trials for UTUC.
Read more →TYRATyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - Advanced “ dabogratinib 3x3 ” strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG
Tyra Biosciences has reported its Q1 2026 financial results, highlighting the progress of its dabogratinib 3x3 strategy aimed at developing treatments for LG-UTUC, IR NMIBC, and achondroplasia. The company has dosed its first patient in the SURF303 trial, with significant initial results expected by 2027. They are also anticipating key data readouts from ongoing Phase 2 studies throughout 2026. Despite a net loss increase, Tyra's robust financial position is expected to support its clinical endeavors until at least late 2028.
Read more →TYRATyra Biosciences to Participate in Upcoming Investor Conferences
Tyra Biosciences, a clinical-stage biotechnology firm, announced its participation in several upcoming investor conferences, including the BofA Securities Health Care Conference and the Jefferies Global Healthcare Conference. These events will feature virtual and hybrid formats, allowing for direct engagement with investors. Tyra aims to highlight its innovative precision medicines targeting FGFR biology.
Read more →TYRATyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Tyra Biosciences has appointed Habib Dable to its Board of Directors, bringing over 30 years of biopharmaceutical leadership experience. Dable's background includes significant roles at Acceleron Pharma and Bayer AG, where he oversaw major product launches. His appointment is seen as pivotal for TYRA as it seeks to advance its pipeline and commercialize its FGFR3 inhibitor, dabogratinib.
Read more →TYRATyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights - Launched “ dabogratinib 3x3 ” strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and A
Tyra Biosciences announced its financial results for Q4 and FY 2025, highlighting the launch of its 'dabogratinib 3x3' strategy aimed at advancing three late-stage clinical studies, targeting indications such as LG-UTUC, IR NMIBC, and ACH. The company reported a cash position of $256 million, ensuring operational support through 2027. Interim clinical data readouts for ongoing studies are expected in 2026. However, the company continues to incur losses, with Q4 2025 showing a net loss of $33.8 million amidst rising R&D expenses.
Read more →TYRATyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights - Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - - Expanded development o
Tyra Biosciences has reported its financial results for the third quarter of 2025, indicating significant advancement in its clinical trials for dabogratinib. The company has dosed its first patients in the BEACH301 and SURF302 studies while expanding dabogratinib's application to low-grade upper tract urothelial carcinoma. Although the company holds a strong financial position with $274.9 million in reserves, it continues to face increasing operating losses and expenses. Interim results from its studies are expected to be announced in 2026, which could validate the drug's broader potential.
Read more →TYRATyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketabl
Tyra Biosciences has reported its financial results for the second quarter of 2025, highlighting significant advancements including the dosing of the first patient in the SURF302 clinical trial for intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The company's cash, cash equivalents, and marketable securities totaled $296.3 million, ensuring operational runway through at least 2027. In addition to SURF302, multiple clinical trials, including those for pediatric achondroplasia and advanced cancers, are currently advancing, supporting the firm’s focus on precision medications targeting FGFR biology.
Read more →TYRA▲ +10.3%on this news
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 f
Tyra Biosciences has reported substantial progress in its first quarter 2025 financial results, highlighting the opening of enrollment for the BEACH301 study of TYRA-300, targeting pediatric achondroplasia. The company also initiated dosing for its SURF431 study of TYRA-430 aimed at hepatocellular carcinoma. Financially, Tyra holds $318.9 million in cash and equivalents, providing a runway until at least 2027, despite experiencing increased net losses and rising research and development expenses. The advancements in clinical trials signify ongoing efforts in the development of next-generation precision therapies.
Read more →TYRA▼ -5.7%on this news
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 st
Tyra Biosciences announced significant advancements in its clinical pipeline and financial results for the year ending December 31, 2024. The company achieved FDA clearance for three Investigational New Drug applications for its precision small molecule TYRA-300, which is set to be evaluated in three Phase 2 studies. Financially, Tyra reported $341.4 million in cash, ensuring operational funding through at least 2027, although it also recorded a net loss increase year-over-year. Leadership transitions aim to strengthen the company's oncology strategies and clinical development.
Read more →TYRATyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of
Tyra Biosciences announced positive interim clinical results for its drug TYRA-300 in metastatic urothelial carcinoma (mUC) from the SURF301 Phase 1/2 study. The company also received IND clearance for a Phase 2 study of TYRA-300 in pediatric achondroplasia. Financial results for Q3 2024 show a net loss of $24.0 million, reflecting increased research and development expenses. Despite the losses, Tyra's cash reserves remain strong at $360.1 million, enabling continued development efforts.
Read more →TYRA▼ -23.3%on this news· ran to -44% by day 3
Today's participants and agenda AGENDA Introduction Todd Interim SURF301 TYRA-300 results Doug Q&A: Perspective of a leading Urologist Gary Todd Harris, PhD Doug Warner, MD Gary Steinberg, MD CEO, TYRA CMO, TYRA Professo
TYRA has presented interim clinical results for TYRA-300, an oral selective FGFR3 inhibitor, indicating promise in treating metastatic urothelial carcinoma (mUC). The treatment has shown anti-tumor activity and an improved safety profile compared to existing therapies. However, the results are preliminary and subject to change, underscoring the inherent risks and uncertainties involved in clinical trials and regulatory approvals.
Read more →TYRA▼ -23.3%on this news· ran to -44% by day 3shared move
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
Tyra Biosciences has reported interim clinical proof-of-concept data for TYRA-300, an investigational oral FGFR3-selective inhibitor, in its Phase 1/2 SURF301 study targeting metastatic urothelial cancer. The results show promising anti-tumor activity, with over half of the patients achieving a confirmed partial response. The safety profile appears favorable, with minimal associated toxicities.
Read more →TYRATyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights - SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstr
Tyra Biosciences reported its Q2 2024 financial results, highlighting significant advancements in their clinical pipeline. They achieved preclinical proof-of-concept for TYRA-300 aimed at hypochondroplasia and received IND clearance for TYRA-430 targeting hepatocellular carcinoma. The company also announced a transition in its Chief Medical Officer position and continues to maintain a robust cash position of $373.8 million. Despite a net loss increasing from the previous year, Tyra remains focused on their clinical studies and operational execution.
Read more →TYRATyra Biosciences Reports First Quarter 2024 Financial Results and Highlights - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and ma
Tyra Biosciences announced its first quarter 2024 financial results, reporting a net loss of $18.2 million. The company remains on track to submit an Investigational New Drug application for TYRA-300 in the second half of 2024, targeting treatments for achondroplasia and oncology. Recent board appointments may positively impact corporate governance. The company reported a healthy cash position of $382.5 million, ensuring operational funding through at least 2026.
Read more →TYRATyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submis
Tyra Biosciences has reported solid financial results for Q4 and the full year 2023, highlighting advancements in its pipeline, including the SURF301 Phase 1 oncology study and the ongoing development of TYRA-300 for achondroplasia. The company has successfully secured a $200 million private placement, enhancing its financial stability going into 2024. FDA grants of Rare Pediatric Disease and Orphan Drug Designations for TYRA-300 indicate significant progress in its targeted indications. However, despite these positive developments, the company also reported an increase in net loss and R&D expenses for the fourth quarter compared to the previous year.
Read more →TYRA▲ +29.3%on this news
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
Tyra Biosciences has announced a successful completion of a $200 million private placement financing to bolster its financial resources. The funding will primarily support the development of its clinical candidates, including TYRA-300, an FGFR3-selective inhibitor for treating various conditions. The PIPE was led by RA Capital Management with participation from esteemed institutional investors. Closing of the financing is anticipated around February 6, 2024, pending customary conditions.
Read more →TYRA▼ -5%on this news
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights - Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia
Tyra Biosciences reported its financial results for Q3 2023, highlighting ongoing activities in its SURF301 Phase 1/2 oncology study with the FGFR3-selective inhibitor TYRA-300. The company presented positive preclinical data for TYRA-300 in achondroplasia at ASBMR and ASHG meetings. Additionally, Tyra announced plans to initiate a Phase 1 study for TYRA-200 by year-end 2023, bolstered by a significant cash position of $215.7 million, despite reporting a net loss for the quarter.
Read more →TYRATyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
Tyra Biosciences reported its Q2 2023 financial results, highlighting the Orphan Drug Designation for TYRA-300 aimed at treating achondroplasia. The company maintains a strong cash position of $232.4 million and continues to progress with its SURF301 Phase 1/2 oncology study. The first patient for the TYRA-200 Phase 1 study is expected to be dosed in the second half of 2023.
Read more →TYRATyra Biosciences Reports First Quarter 2023 Financial Results and Highlights -SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared
Tyra Biosciences reported its first quarter 2023 financial results, highlighting significant advancements in its clinical programs. The company is progressing well with its SURF301 Phase 1/2 oncology study for TYRA-300 and has expanded its development into achondroplasia. Additionally, the FDA has cleared the IND for TYRA-200, with expectations to initiate a Phase 1 trial in the second half of 2023. Tyra ended the quarter with a strong cash position of $241.7 million.
Read more →TYRA▼ -5%on this news
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights -Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined c
Tyra Biosciences reported its fourth quarter and full year 2022 financial results, highlighting significant corporate progress, including the initiation of patient dosing with TYRA-300 in the SURF301 oncology study and the expansion into achondroplasia. The company had a strong cash position of $251.2 million as of year-end 2022, ensuring more than two years of runway for its development plans. However, Tyra reported increased net losses in both the fourth quarter and the full year compared to previous years.
Read more →TYRA▼ -7%on this news
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights -Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivale
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights -Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD, Calif., No
Read more →TYRA▲ +5.5%on this news
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Tyra Biosciences will present preclinical data on its FGFR1/2/3 inhibitor, TYRA-200, at the 34th EORTC-NCI-AACR Symposium in Barcelona. The data will focus on the drug's effectiveness against FGFR2 fusions and resistance mutations. The presentation is scheduled for October 26, 2022, during a poster session.
Read more →TYRA▲ +8.2%on this news· ran to +20% by day 3
Tyra Biosciences to Participate at September 2022 Investor Conferences
Tyra Biosciences, a precision oncology company, announced its participation in two investor conferences: H.C. Wainwright's 24th Annual Global Investment Conference and the Cantor Oncology, Hematology & HemeOnc Conference. The company is focused on developing therapies to overcome tumor resistance, leveraging its proprietary SNÅP platform. Tyra is advancing a pipeline of selective FGFR inhibitors targeting various cancers.
Read more →TYRATyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights -IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights -IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 mil
Read more →TYRATyra Biosciences Reports First Quarter 2022 Financial Results and Highlights -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as o
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of CARLSBAD, Calif., May 5, 2022 Tyra Biosciences, Inc. (N
Read more →TYRA▼ -10.2%on this news
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment to clinical team- -Well-capitalized with cash and cash
Read more →TYRATyra Biosciences to Present at the 2021 Jefferies London Healthcare Conference
Tyra Biosciences, a precision oncology company, will present at the 2021 Jefferies London Healthcare Conference. The event will feature a fireside chat and one-on-one investor meetings from November 18-19, 2021. The company aims to develop therapies targeting tumor resistance, particularly focusing on FGFR inhibitors for various cancers.
Read more →TYRA▲ +19.9%on this news
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights -Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of
Tyra Biosciences Reports Third Quarter 2021 Financial Results and Highlights -Successful completion of upsized $198.7 million initial public offering; cash and cash equivalents of $312.8 million as of -Nominated 2nd product candidate for clinical development, TYRA-200 (FGFR2 i
Read more →TYRA▼ -6.8%on this news
Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Tyra Biosciences, Inc. has successfully closed its initial public offering, raising $198.72 million by selling 12,420,000 shares at $16.00 each. The offering included the full exercise of the underwriters' option to purchase additional shares. Tyra focuses on developing targeted therapies for cancer treatment, particularly through its proprietary SNÅP platform.
Read more →TYRATyra Announces Pricing of Upsized Initial Public Offering Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and...
BofA Securities, Jefferies and Cowen are acting as joint book-running managers for the offering. Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on September 14, 2021. The offering will be made onl
Read more →Competitive Position
How TYRA ranks across every disease it competes inCompetitive Position is a premium feature
See how TYRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial